IGC Pharma, Inc. annual report, FY2024

Vollständiges Dokument

IGC Pharma, Inc. — Fiscal 2024 Form 10-K

Reporting period: Fiscal year ended March 31, 2024, compared with fiscal 2023 ended March 31, 2023. This is an annual report, not a report for calendar 2023 Q4.

Business context

IGC is a clinical-stage company focused on Alzheimer’s treatments, with a smaller over-the-counter wellness business and an infrastructure business involving construction contracts and heavy-equipment rentals. Its lead candidate, IGC-AD1, is in a Phase 2 trial for agitation in Alzheimer’s dementia. Four other Alzheimer’s candidates are in preclinical development. The company also describes AI initiatives and a portfolio of 28 patent filings.

Financial performance and liquidity

  • Revenue: $1.345 million, up 48% from $0.911 million. Life Sciences contributed $1.181 million (88%); Infrastructure contributed $164,000 (12%). White-label services rose to $953,000 from $382,000, while wellness and lifestyle sales declined to $228,000 from $416,000.
  • Gross profit and margin: $733,000 and approximately 54%, versus $442,000 and approximately 49% in fiscal 2023.
  • Operating results: Operating loss was $9.798 million, improved from $11.571 million as SG&A declined 21% to $6.758 million. R&D increased 9% to $3.773 million.
  • Net loss: $13.000 million, compared with $11.506 million. The fiscal 2024 result included a $3.345 million impairment of Nagpur land; there was no comparable impairment in fiscal 2023. Loss per share was $0.22 in both years.
  • Cash flow: Operating cash use was $5.199 million, versus $7.047 million. Investing cash use was $317,000; financing provided $3.524 million. Cash declined by $1.998 million during the year.
  • Liquidity: Cash and equivalents were $1.198 million at year-end, down from $3.196 million; working capital was $1.365 million, down from $4.568 million. Inventory declined to $1.540 million from $2.651 million, following approximately $1 million of inventory write-offs during fiscal 2024.
  • Debt and obligations: The balance sheet showed $137,000 of long-term loans and approximately $3,000 of short-term loans, principally the remaining SBA disaster loan. Operating lease liabilities totaled $208,000. The company also reports a $12 million working-capital credit facility; the filing does not clearly state how much was drawn at year-end.
  • Capital raising and dilution: Fiscal 2024 financing cash flow included $3.027 million of net common-stock proceeds and $500,000 of stock subscriptions. Under a March 2024 share purchase agreement, the company reported a $3 million placement; $500,000 had been received by year-end and the remaining $2.5 million arrived in April 2024. The agreement provides for approximately 8.8 million shares, with an additional 2 million shares issued for capital-raising consulting services. The company also has an ATM program with an aggregate offering limit of up to $60 million, subject to limitations.

Material changes versus fiscal 2023

  • Revenue increased, chiefly because white-label services grew, but the company remained loss-making and operating cash flow remained negative.
  • SG&A fell, while R&D spending rose as the IGC-AD1 Phase 2 trial and TGR-63 preclinical work progressed.
  • Net loss worsened largely due to the land impairment, despite an improved operating loss.
  • Year-end cash and working capital fell materially. Common shares outstanding increased from 53.1 million to 66.7 million at fiscal year-end; 75.6 million were outstanding on June 18, 2024.

Outlook, commentary, risks and contingencies

  • Clinical program: The company reported positive prespecified interim Phase 2 results based on 26 patients in an ongoing, planned 146-patient trial. CMAI agitation-score differences versus placebo were -12.19 at week two (p=0.071) and -10.46 at week six (p=0.042); the week-six result was the interim primary endpoint. The filing cautions that the small interim sample may not predict final results. The company says the trial continues enrolling; it expects further R&D expense increases. It also reported over 1,000 administered doses without observed dose-limiting adverse events, which does not establish safety or efficacy in a larger population.
  • Funding outlook: Management expects current cash, working capital and equity funding to support operations for more than 12 months from issuance of the financial statements, but this depends on assumptions. The company expects to renew the one-year $12 million credit facility and seeks additional private-placement, ATM and potentially non-dilutive funding; success and terms are not assured. It has a history of substantial losses and states that further financing may be needed, potentially diluting shareholders.
  • Development and regulatory risks: IGC-AD1 is investigational and requires successful further trials and regulatory approval. Clinical enrollment, trial outcomes, manufacturing, FDA requirements, THC/hemp regulation, market acceptance and reimbursement remain uncertain. Management’s comparison of interim results with an approved competing treatment is not a direct head-to-head trial.
  • Other risks and unusual items: Customer concentration was reported in both segments; two customers each represented more than 10% of Life Sciences sales and one customer more than 10% of Infrastructure sales. The company plans to sell non-core assets, including impaired Nagpur land, and may realize less than book value. It identifies financing access challenges associated with perceptions of cannabinoid businesses, possible equity dilution, currency exposure, and cybersecurity and AI risks.
  • Legal matters: The Apogee litigation was dismissed in its entirety in October 2023 after the court’s July 2023 rulings and a settlement. A contractual dispute and complaint involving Engineering and Consulting Group SAS in Colombia remained in process; a hearing was scheduled and accepted for 2024. The company said no legal matters were deemed material to the financial statements at March 31, 2024.
  • Audit and controls: The auditor issued an unqualified opinion and reported no critical audit matters. The auditor was not engaged to audit internal control; management concluded disclosure controls and internal control over financial reporting were effective as of March 31, 2024.
  • Guidance: The filing provides no formal numerical revenue or earnings guidance.

Important facts for investors to verify

  • Check subsequent Phase 2 enrollment, full-trial results, safety findings and regulatory discussions; assess the interim sample size and statistical results in context.
  • Confirm the amount drawn, availability, terms and renewal status of the $12 million credit facility, and whether additional financing is required.
  • Reconcile the March placement proceeds, share issuance and consulting shares with the latest share count and assess potential dilution from the ATM and equity awards.
  • Track cash burn, working capital, inventory quality and write-offs, and whether planned non-core asset sales produce the expected proceeds.
  • Review revenue concentration and whether white-label growth is repeatable, alongside the company’s ability to grow revenue toward operating break-even.
  • Monitor the Colombia dispute, regulatory changes affecting hemp-derived THC, and any changes to the company’s financing or listing access.